Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

2000 volunteers needed to help spot lung cancer earlier

NCT ID NCT07401797

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study collects samples and health information from 2,000 people with lung nodules to find the best way to detect lung cancer early. Participants must have a nodule at least 5mm wide and plan to have a biopsy, PET scan, or follow-up within 7 months. The goal is to improve how doctors identify cancer and guide treatment, but test results won't be shared with doctors or affect actual care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 2,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2024

Expected to finish

Dec 2029

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Individuals over 18 years old with indeterminate lung nodules identified on CT scans.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

6.1 Criteria for the no prior cancer suspicious nodule arm Inclusion: 1. The patient has at least one indeterminant nodule with a diameter greater than or equal to 5mm and a Mayo SPN risk greater than 5%, identified by radiology, that has not been biopsied or undergone surgery. 2. The patient and the treating physician intend to follow up on the nodule with a biopsy procedure, PET scan, or active surveillance, with the procedure or next surveillance planned within the next 7 months. 3. Ability to understand the study and sign an informed consent form 4. Relevant clinical data accessible 5. Ability and willingness to safely donate 40 mL of blood 6. Ability of the site to collect and process blood per protocol Exclusion 1\. The patient has one or more nodules with a Mayo SPN risk over 50% or a diameter of 30mm or greater. 2\. The patient has received surgical prep, including antibiotics, anesthesia, etc. Fasting is not exclusionary. 3\. Previous cancer diagnosis of any origin. 4. Is currently pregnant 5. Is currently a prisoner or becomes a prisoner at any point during the study 6. Is under age 18, is unable to consent, or requires a different person or entity to consent on their behalf 6.2 Criteria for the previous cancer suspicious nodule arm Inclusion: 1\. The patient has at least one indeterminant nodule with a diameter greater than or equal to 5mm and a Mayo SPN risk greater than 5%, identified by radiology, that has not been biopsied or undergone surgery. 2\. The patient and the treating physician intend to follow up on the nodule with a biopsy procedure, PET scan, or active surveillance, with the procedure or next surveillance planned within the next 7 months. 3\. The patient has been in remission for a previous cancer not of lung origin for more than 5 years. 4\. Ability to understand the study and sign an informed consent form 5. Relevant clinical data accessible 6. Ability and willingness to safely donate 40 mL of blood 7. Ability of the site to collect and process blood per protocol Exclusion 1. The patient has one or more nodules with a Mayo SPN risk over 50% or a diameter of 30mm or greater. 2. The patient has received surgical prep, including antibiotics, anesthesia, etc. Fasting is not exclusionary. 3. Previous cancer diagnosis in the lung (either of lung origin or metastasis to the lung). 4. The treating physician believes the lung nodule is a recurrence of a previously diagnosed cancer. 5. Is currently pregnant 6. Is currently a prisoner or becomes a prisoner at any point during the study 7. Is under age 18, is unable to consent, or requires a different person or entity to consent on their behalf 6.3 Criteria for the healthy volunteer arm Inclusion: 1. Ability to understand the study and sign an informed consent form 2. Relevant clinical data accessible 3. Ability and willingness to safely donate up to 40 mL of blood 4. The ability of the site to collect and process blood per protocol Exclusion 1\. Is currently pregnant 2. Is currently a prisoner or becomes a prisoner at any point during the study 3. Is under age 18, is unable to consent, or requires a different person or entity to consent on their behalf

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Lung cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Maverix Medical

    RECRUITING

    Phoenix, Arizona, 85004, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.